(IRTC) iRhythm Technologies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4500561067
Stock: Patch, Monitor, Telemetry, Software, Gateway
Total Rating 51
Risk 51
Buy Signal -0.81
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 54.9% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.79 |
| Alpha | 18.97 |
| Character TTM | |
|---|---|
| Beta | 0.757 |
| Beta Downside | 0.546 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.15% |
| CAGR/Max DD | 0.21 |
Description: IRTC iRhythm Technologies January 10, 2026
iRhythm Technologies, Inc. (NASDAQ: IRTC) develops and commercializes prescription-only, patch-based ECG monitoring systems-including the Zio, Zio XT, and Zio AT platforms-that continuously record cardiac activity for up to 14 days, enabling clinicians to diagnose arrhythmias such as atrial fibrillation across the United States.
In its most recent fiscal year (2023), iRhythm reported revenue of roughly $322 million, a year-over-year increase of about 15%, and maintained a cash balance of $120 million, providing runway for R&D and partnership initiatives.
The ambulatory cardiac monitoring market is expanding at a compound annual growth rate of 9%–11% driven by an aging U.S. population, rising AFib prevalence (projected to affect >12 million adults by 2030), and broader reimbursement support for remote cardiac diagnostics under Medicare and private payer policies.
For a deeper quantitative analysis, the ValueRay platform offers a detailed IRTC valuation model that can help you assess the stock’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -51.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 11.22 > 1.0 |
| NWC/Revenue: 75.88% < 20% (prev 94.25%; Δ -18.36% < -1%) |
| CFO/TA 0.07 > 3% & CFO 73.9m > Net Income -51.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.6m) vs 12m ago 4.20% < -2% |
| Gross Margin: 70.35% > 18% (prev 0.68%; Δ 6967 % > 0.5%) |
| Asset Turnover: 73.76% > 50% (prev 61.56%; Δ 12.20% > 0%) |
| Interest Coverage Ratio: -2.98 > 6 (EBITDA TTM -15.2m / Interest Expense TTM 13.2m) |
Altman Z'' -0.39
| A: 0.54 (Total Current Assets 680.0m - Total Current Liabilities 146.9m) / Total Assets 995.2m |
| B: -0.81 (Retained Earnings -809.0m / Total Assets 995.2m) |
| C: -0.04 (EBIT TTM -39.2m / Avg Total Assets 952.5m) |
| D: -0.93 (Book Value of Equity -808.7m / Total Liabilities 873.3m) |
| Altman-Z'' Score: -0.39 = B |
Beneish M -3.19
| DSRI: 0.78 (Receivables 76.2m/77.4m, Revenue 702.6m/560.0m) |
| GMI: 0.96 (GM 70.35% / 67.83%) |
| AQI: 0.98 (AQ_t 0.12 / AQ_t-1 0.13) |
| SGI: 1.25 (Revenue 702.6m / 560.0m) |
| TATA: -0.13 (NI -51.5m - CFO 73.9m) / TA 995.2m) |
| Beneish M-Score: -3.19 (Cap -4..+1) = AA |
What is the price of IRTC shares?
As of February 08, 2026, the stock is trading at USD 146.47 with a total of 893,358 shares traded.
Over the past week, the price has changed by -5.20%, over one month by -20.82%, over three months by -17.44% and over the past year by +34.93%.
Over the past week, the price has changed by -5.20%, over one month by -20.82%, over three months by -17.44% and over the past year by +34.93%.
Is IRTC a buy, sell or hold?
iRhythm Technologies has received a consensus analysts rating of 4.62.
Therefore, it is recommended to buy IRTC.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IRTC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 221.3 | 51.1% |
| Analysts Target Price | 221.3 | 51.1% |
| ValueRay Target Price | 146.5 | 0% |
IRTC Fundamental Data Overview February 03, 2026
P/S = 7.0856
P/B = 39.3815
Revenue TTM = 702.6m USD
EBIT TTM = -39.2m USD
EBITDA TTM = -15.2m USD
Long Term Debt = 648.8m USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 733.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 477.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.15b USD (4.98b + Debt 733.0m - CCE 565.2m)
Interest Coverage Ratio = -2.98 (Ebit TTM -39.2m / Interest Expense TTM 13.2m)
EV/FCF = 158.7x (Enterprise Value 5.15b / FCF TTM 32.4m)
FCF Yield = 0.63% (FCF TTM 32.4m / Enterprise Value 5.15b)
FCF Margin = 4.61% (FCF TTM 32.4m / Revenue TTM 702.6m)
Net Margin = -7.32% (Net Income TTM -51.5m / Revenue TTM 702.6m)
Gross Margin = 70.35% ((Revenue TTM 702.6m - Cost of Revenue TTM 208.3m) / Revenue TTM)
Gross Margin QoQ = 71.09% (prev 71.17%)
Tobins Q-Ratio = 5.17 (Enterprise Value 5.15b / Total Assets 995.2m)
Interest Expense / Debt = 0.45% (Interest Expense 3.28m / Debt 733.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -31.0m (EBIT -39.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.63 (Total Current Assets 680.0m / Total Current Liabilities 146.9m)
Debt / Equity = 6.01 (Debt 733.0m / totalStockholderEquity, last quarter 121.9m)
Debt / EBITDA = -31.40 (negative EBITDA) (Net Debt 477.4m / EBITDA -15.2m)
Debt / FCF = 14.73 (Net Debt 477.4m / FCF TTM 32.4m)
Total Stockholder Equity = 100.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.40% (Net Income -51.5m / Total Assets 995.2m)
RoE = -51.06% (Net Income TTM -51.5m / Total Stockholder Equity 100.8m)
RoCE = -5.23% (EBIT -39.2m / Capital Employed (Equity 100.8m + L.T.Debt 648.8m))
RoIC = -4.14% (negative operating profit) (NOPAT -31.0m / Invested Capital 748.4m)
WACC = 7.63% (E(4.98b)/V(5.71b) * Re(8.70%) + D(733.0m)/V(5.71b) * Rd(0.45%) * (1-Tc(0.21)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.01%
[DCF Debug] Terminal Value 75.42% ; FCFF base≈32.4m ; Y1≈25.2m ; Y5≈16.2m
Fair Price DCF = N/A (negative equity: EV 323.1m - Net Debt 477.4m = -154.3m; debt exceeds intrinsic value)
EPS Correlation: 51.26 | EPS CAGR: 27.67% | SUE: 0.03 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 25.70% | SUE: 2.12 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.029 | Revisions Net=+2 | Analysts=9
EPS next Year (2026-12-31): EPS=-0.29 | Chg30d=+0.011 | Revisions Net=+2 | Growth EPS=+77.0% | Growth Revenue=+17.4%
P/B = 39.3815
Revenue TTM = 702.6m USD
EBIT TTM = -39.2m USD
EBITDA TTM = -15.2m USD
Long Term Debt = 648.8m USD (from longTermDebt, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 733.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 477.4m USD (from netDebt column, last quarter)
Enterprise Value = 5.15b USD (4.98b + Debt 733.0m - CCE 565.2m)
Interest Coverage Ratio = -2.98 (Ebit TTM -39.2m / Interest Expense TTM 13.2m)
EV/FCF = 158.7x (Enterprise Value 5.15b / FCF TTM 32.4m)
FCF Yield = 0.63% (FCF TTM 32.4m / Enterprise Value 5.15b)
FCF Margin = 4.61% (FCF TTM 32.4m / Revenue TTM 702.6m)
Net Margin = -7.32% (Net Income TTM -51.5m / Revenue TTM 702.6m)
Gross Margin = 70.35% ((Revenue TTM 702.6m - Cost of Revenue TTM 208.3m) / Revenue TTM)
Gross Margin QoQ = 71.09% (prev 71.17%)
Tobins Q-Ratio = 5.17 (Enterprise Value 5.15b / Total Assets 995.2m)
Interest Expense / Debt = 0.45% (Interest Expense 3.28m / Debt 733.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -31.0m (EBIT -39.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.63 (Total Current Assets 680.0m / Total Current Liabilities 146.9m)
Debt / Equity = 6.01 (Debt 733.0m / totalStockholderEquity, last quarter 121.9m)
Debt / EBITDA = -31.40 (negative EBITDA) (Net Debt 477.4m / EBITDA -15.2m)
Debt / FCF = 14.73 (Net Debt 477.4m / FCF TTM 32.4m)
Total Stockholder Equity = 100.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.40% (Net Income -51.5m / Total Assets 995.2m)
RoE = -51.06% (Net Income TTM -51.5m / Total Stockholder Equity 100.8m)
RoCE = -5.23% (EBIT -39.2m / Capital Employed (Equity 100.8m + L.T.Debt 648.8m))
RoIC = -4.14% (negative operating profit) (NOPAT -31.0m / Invested Capital 748.4m)
WACC = 7.63% (E(4.98b)/V(5.71b) * Re(8.70%) + D(733.0m)/V(5.71b) * Rd(0.45%) * (1-Tc(0.21)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.01%
[DCF Debug] Terminal Value 75.42% ; FCFF base≈32.4m ; Y1≈25.2m ; Y5≈16.2m
Fair Price DCF = N/A (negative equity: EV 323.1m - Net Debt 477.4m = -154.3m; debt exceeds intrinsic value)
EPS Correlation: 51.26 | EPS CAGR: 27.67% | SUE: 0.03 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 25.70% | SUE: 2.12 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.029 | Revisions Net=+2 | Analysts=9
EPS next Year (2026-12-31): EPS=-0.29 | Chg30d=+0.011 | Revisions Net=+2 | Growth EPS=+77.0% | Growth Revenue=+17.4%